Dura Substitute Market (Material: Biological Grafts and Synthetic Grafts; Application: Neurosurgery and Spinal Surgery; and End-user: Hospitals, Ambulatory Surgical Center, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2030

The global Dura Substitute market gathered revenue around USD 176.1 Million in 2021 and market is set to grow USD 328.1 Million by the end of 2030 and is estimated to expand at a modest CAGR of 5.2% during the prediction period 2022 to 2030.

Growth Factors:

Prevalence of CNS tumors caused by neurological disorders is increasing. Chiari malformation and spinal cord tumor-related neurosurgery procedures that necessitate dural grafts have become more common.

Rise in prevalence of neurological diseases requires neurosurgical treatments as well as duraplasty for effective and safe treatment outcomes. In 2018, more than half of all dural substitutes were utilized in cranial and spine tumor surgeries. This is expected to continue in the near future. Therefore, rise in prevalence of neurosurgical diseases leads to an increase in cranial and spinal duraplasty procedures, which in turn is anticipated to boost the demand for dura substitutes.

Researchers have attempted to employ various synthetic polymers to make dural substitutes in order to minimize the spread of diseases caused by the use of allogeneic or xenogeneic materials, increase clinical effectiveness, and reduce costs

Synthetic macromolecular materials, in comparison to collagen-based dura substitutes, lack the biological functions of stimulating cell migration and boosting the production of related cytokines. Scientists have attempted to create dura substitutes by incorporating gelatin or silk fibroin into the polymer. This approach not only assures the bionic structure of the dural replacement, but also enhances the material's biological function and surface properties, improving its repair effects.

Therefore, benefits such as enhanced clinical effectiveness, increased safety, and minimal adverse effects associated with synthetic dura substitutes are anticipated to fuel the growth of the dura substitute market

Report Scope of the Dura Substitute Market

Report Coverage

Details

Market Size

US$ 328.1 Million by 2030

Growth Rate

CAGR of 5.2% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year

2021

Forecast Period

2022 to 2030

Segments Covered

Material, Application, End-user and Region,

Companies Mentioned

 Cook Medical LLC, B. Braun Melsungen AG, Integra LifeSciences, Cousin Surgery, W. L. Gore & Associates, Inc., Biosynth Lifesciences, Acera Surgical, Inc., Medprin, Medtronic, Stryker, DePuy Synthes, Gunze Limited, Baxter, Bennett Health, Inc., RTI Surgical, Natus Medical Incorporated

Dura Substitute Market: Overview

Dural substitute is a type of medical device used in surgeries to repair dura mater, the outermost layer that covers and protects the brain. Animal collagen or nanofibers woven together with an elastic material to form a soft tamponade can also be used to create a dural substitute.

Dural substitutes are required to prevent CSF leaks and to allow dural openings to heal after surgery. Dural substitutes can be biological or synthetic, harvested from animals or human cadavers, and used as an onlay or suturable grafts. The key advantage of using a dural substitute is that it is similar to the patient's dura and can absorb and integrate into the host tissue.

Rise in the number of road accidents and sports injuries, which increases the need of neurosurgery, is the major factor boosting market growth. However, product recalls is likely to hamper market growth.

Government Funding in Regenerative Medicine Contributing to Market Growth

Government funding for the treatment of various diseases is increasing globally due to the formulation and adoption of supporting legislation & policies. Such trends are contributing to expansion of the regenerative medicine sector in the dura substitute market.

Healthcare companies are drawing significant expenditure in regenerative medicines such as the establishment of centers of excellence, manufacturing infrastructure, and research networks, among others. The NIH (National Institutes of Health) Common Fund facilitated the establishment of the NIH Center for Regenerative Medicine in 2010 with the purpose of serving as a national resource for stem cell sciences. Such developments are helping to accelerate the development of novel medical applications and cell-based therapeutics.

Transition from Animal Tissue-derived Materials to Synthetic Materials Aiding Market Growth

Dural repair materials are transitioning from animal tissue-derived materials to synthetic materials as well as from inert to absorbable properties. Such findings are bringing a significant change in the global dura substitute market.

Biomimetic patch is a new dural repair product that provides functional properties similar to alternate therapies. This patch has a 3 dimensional (3D) non-woven microfiber structure that is both mechanically strong and biocompatible. The animal investigation revealed that the biomimetic patch and commercially synthesized material groups demonstrated new subdural regeneration after 90 days, with low inflammatory response and minimal to no adhesion development at each stage. It has been found that the biomimetic structure and proper rate of degradation of the new absorbable dura replacement can lead significant regeneration of the dura mater.

Market Segmentation: Dura Substitute Market

In terms of material, the global dura substitute market has been bifurcated into biological graft and synthetic graft. The biological graft segment has been split into autografts, allografts, and xenografts. The synthetic segment has been segregated into polytetrafluoroethylene and others.

Based on application, the global dura substitute market has been classified into neurosurgery and spinal surgery

In terms of end-user, the global dura substitute market has been divided into hospitals, ambulatory surgical centers, and others

Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The dura substitute market report provides current and expected revenue (US$ Mn) for each of these segments from 2022 to 2030, considering 2021 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2022 to 2030 along with market size estimations.

Regional Overview: Dura Substitute Market

In terms of region, the global dura substitute market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa

North America dominated the global dura substitute market in 2021, accounting for 41.9% share. Developed healthcare infrastructure and presence of patient-specific healthcare systems fuel the growth of the dura substitute market in North America.

The U.S. dominated the market in North America due to rapid adoption of new technologies for soft tissue repair, presence of key players, and higher penetration of research activities across the country

Moreover, growing burden of neurosurgical diseases is leading to increase in cranial and spinal duraplasty, which, in turn, is likely to boost the demand for dura substitute in the region

Some of the prominent players in the Dura Substitute Market include:

  • Cook Medical LLC
  • B. Braun Melsungen AG
  • Integra LifeSciences
  • Cousin Surgery
  • W. L. Gore & Associates, Inc.
  • Biosynth Lifesciences
  • Acera Surgical, Inc.
  • Medprin
  • Medtronic
  • Stryker
  • DePuy Synthes
  • Gunze Limited
  • Baxter
  • Bennett Health, Inc.
  • RTI Surgical
  • Natus Medical Incorporated

Segments Covered in the Report

This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:

  • By Material
    • Biological Grafts
      • Autografts
      • Allografts
      • Xenogrfts
        • Decellularized Pericardium
        • Small Intestine Submucosa
        • Collagen
    • Synthetic Grafts
      • Polytetrafluoroethylene (PTFE)
      • Others
  • By Application
    • Neurosurgery
    • Spinal Surgery
  • By End-user
    • Hospitals
    • Ambulatory Surgical Centers
    • Others

By Geography

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Key Points Covered in Dura Substitute Market Study:

  • Growth of Dura Substitute in 2022
  • Market Estimates and Forecasts (2017-2030)
  •  Brand Share and Market Share Analysis
  •  Key Drivers and Restraints Shaping Market Growth
  •  Segment-wise, Country-wise, and Region-wise Analysis
  •  Competition Mapping and Benchmarking
  •  Recommendation on Key Winning Strategies
  •  COVID-19 Impact on Demand for Dura Substitute and How to Navigate
  •  Key Product Innovations and Regulatory Climate
  •  Dura Substitute Consumption Analysis
  •  Dura Substitute Production Analysis
  •  Dura Substitute and Management

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Dura Substitute Market

4. Market Overview

    4.1. Introduction

        4.1.1. Material Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Dura Substitute Market Analysis and Forecast, 2017–2030

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Technological Advancements

    5.2. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)

    5.3. Pricing Analysis

    5.4. Product /Brand Analysis, by Application

    5.5. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Dura Substitute Market Analysis and Forecast, by Material

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Material, 2017–2030

        6.3.1. Biological Grafts

            6.3.1.1. Autografts

            6.3.1.2. Allografts

            6.3.1.3. Xenografts

                6.3.1.3.1. Collagen

                6.3.1.3.2. Decellularized Pericardium

                6.3.1.3.3. Small Intestine Submucosa

        6.3.2. Synthetic

            6.3.2.1. Polytetrafluoroethylene (PTFE)

            6.3.2.2. Others

    6.4. Market Attractiveness Analysis, by Material

7. Global Dura Substitute Market Analysis and Forecast, by Application

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Application, 2017–2030

        7.3.1. Neurosurgery

        7.3.2. Spinal Surgery

    7.4. Market Attractiveness Analysis, by Application

8. Global Dura Substitute Market Analysis and Forecast, by End-user

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by End-user, 2017–2030

        8.3.1. Hospitals

        8.3.2. Ambulatory Surgical Centers

        8.3.3. Others

    8.4. Market Attractiveness Analysis, by End-user

9. Global Dura Substitute Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Dura Substitute Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Material, 2017–2030

        10.2.1. Biological Grafts

            10.2.1.1. Autografts

            10.2.1.2. Allografts

            10.2.1.3. Xenografts

                10.2.1.3.1. Collagen

                10.2.1.3.2. Decellularized Pericardium

                10.2.1.3.3. Small Intestine Submucosa

        10.2.2. Synthetic

            10.2.2.1. Polytetrafluoroethylene (PTFE)

            10.2.2.2. Others

    10.3. Market Value Forecast, by Application, 2017–2030

        10.3.1. Neurosurgery

        10.3.2. Spinal Surgery

    10.4. Market Value Forecast, by End-user, 2017–2030

        10.4.1. Hospitals

        10.4.2. Ambulatory Surgical Centers

        10.4.3. Others

    10.5. Market Value Forecast, by Country, 2017–2030

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Material

        10.6.2. By Application

        10.6.3. By End-user

        10.6.4. By Country

11. U.S Dura Substitute Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Material, 2017–2030

        11.2.1. Biological Grafts

        11.2.2. Synthetic

    11.3. Market Value Forecast, by Application, 2017–2030

        11.3.1. Neurosurgery

        11.3.2. Spinal Surgery

    11.4. Market Attractiveness Analysis

        11.4.1. By Material

        11.4.2. By Application

12. Canada Dura Substitute Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Material, 2017–2030

        12.2.1. Biological Grafts

        12.2.2. Synthetic

    12.3. Market Value Forecast, by Application, 2017–2030

        12.3.1. Neurosurgery

        12.3.2. Spinal Surgery

    12.4. Market Attractiveness Analysis

        12.4.1. By Material

        12.4.2. By Application

13. Europe Dura Substitute Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Material, 2017–2030

        13.2.1. Biological Grafts

            13.2.1.1. Autografts

            13.2.1.2. Allografts

            13.2.1.3. Xenografts

                13.2.1.3.1. Collagen

                13.2.1.3.2. Decellularized Pericardium

                13.2.1.3.3. Small Intestine Submucosa

        13.2.2. Synthetic

            13.2.2.1. Polytetrafluoroethylene (PTFE)

            13.2.2.2. Others

    13.3. Market Value Forecast, by Application, 2017–2030

        13.3.1. Neurosurgery

        13.3.2. Spinal Surgery

    13.4. Market Value Forecast, by End-user, 2017–2030

        13.4.1. Hospitals

        13.4.2. Ambulatory Surgical Centers

        13.4.3. Others

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2030

        13.5.1. Germany

        13.5.2. U.K

        13.5.3. France

        13.5.4. Italy

        13.5.5. Spain

        13.5.6. Denmark

        13.5.7. Sweden

        13.5.8. Finland

        13.5.9. Iceland

        13.5.10. Norway

        13.5.11. Rest of Europe

    13.6. Market Attractiveness Analysis

        13.6.1. By Material

        13.6.2. By Application

        13.6.3. By End-user

        13.6.4. By Country/Sub-region

14. Germany Dura Substitute Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Material, 2017–2030

        14.2.1. Biological Grafts

        14.2.2. Synthetic

    14.3. Market Value Forecast, by Application, 2017–2030

        14.3.1. Neurosurgery

        14.3.2. Spinal Surgery

    14.4. Market Attractiveness Analysis

        14.4.1. By Material

        14.4.2. By Application

15. U.K Dura Substitute Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Material, 2017–2030

        15.2.1. Biological Grafts

        15.2.2. Synthetic

    15.3. Market Value Forecast, by Application, 2017–2030

        15.3.1. Neurosurgery

        15.3.2. Spinal Surgery

    15.4. Market Attractiveness Analysis

        15.4.1. By Material

        15.4.2. By Application

16. France Dura Substitute Market Analysis and Forecast

    16.1. Introduction

        16.1.1. Key Findings

    16.2. Market Value Forecast, by Material, 2017–2030

        16.2.1. Biological Grafts

        16.2.2. Synthetic

    16.3. Market Value Forecast, by Application, 2017–2030

        16.3.1. Neurosurgery

        16.3.2. Spinal Surgery

    16.4. Market Attractiveness Analysis

        16.4.1. By Material

        16.4.2. By Application

17. Italy Dura Substitute Market Analysis and Forecast

    17.1. Introduction

        17.1.1. Key Findings

    17.2. Market Value Forecast, by Material, 2017–2030

        17.2.1. Biological Grafts

        17.2.2. Synthetic

    17.3. Market Value Forecast, by Application, 2017–2030

        17.3.1. Neurosurgery

        17.3.2. Spinal Surgery

    17.4. Market Attractiveness Analysis

        17.4.1. By Material

18. Competition Landscape

    18.1. Market Player - Competition Matrix (by tier and size of companies)

    18.2. Market Share Analysis, by Company, 2020

    18.3. Company Profiles

        18.3.1. Cook Medical LLC

            18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.1.2. Product Portfolio

            18.3.1.3. SWOT Analysis

            18.3.1.4. Strategic Overview

        18.3.2. B. Braun Melsungen AG

            18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.2.2. Product Portfolio

            18.3.2.3. SWOT Analysis

            18.3.2.4. Strategic Overview

        18.3.3. Integra LifeSciences

            18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.3.2. Product Portfolio

            18.3.3.3. SWOT Analysis

            18.3.3.4. Strategic Overview

        18.3.4. Cousin Surgery

            18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.4.2. Product Portfolio

            18.3.4.3. SWOT Analysis

            18.3.4.4. Strategic Overview

        18.3.5. W. L. Gore & Associates, Inc.

            18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.5.2. Product Portfolio

            18.3.5.3. SWOT Analysis

            18.3.5.4. Strategic Overview

        18.3.6. Biosynth Lifesciences

            18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.6.2. Product Portfolio

            18.3.6.3. SWOT Analysis

            18.3.6.4. Strategic Overview

        18.3.7. Acera Surgical, Inc.

            18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.7.2. Product Portfolio

            18.3.7.3. SWOT Analysis

            18.3.7.4. Strategic Overview

        18.3.8. Medprin

            18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.8.2. Product Portfolio

            18.3.8.3. SWOT Analysis

            18.3.8.4. Strategic Overview

        18.3.9. Medtronic

            18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.9.2. Product Portfolio

            18.3.9.3. SWOT Analysis

            18.3.9.4. Strategic Overview

        18.3.10. Stryker

            18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.10.2. Product Portfolio

            18.3.10.3. SWOT Analysis

            18.3.10.4. Strategic Overview

        18.3.11. DePuy Synthes

            18.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.11.2. Product Portfolio

            18.3.11.3. SWOT Analysis

            18.3.11.4. Strategic Overview

        18.3.12. Gunze Limited

            18.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.12.2. Product Portfolio

            18.3.12.3. SWOT Analysis

            18.3.12.4. Strategic Overview

        18.3.13. Baxter

            18.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.13.2. Product Portfolio

            18.3.13.3. SWOT Analysis

            18.3.13.4. Strategic Overview

        18.3.14. Bennett Health, Inc.

            18.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.14.2. Product Portfolio

            18.3.14.3. SWOT Analysis

            18.3.14.4. Strategic Overview

        18.3.15. RTI Surgical

            18.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.15.2. Product Portfolio

            18.3.15.3. SWOT Analysis

            18.3.15.4. Strategic Overview

        18.3.16. Natus Medical Incorporated

            18.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)

            18.3.16.2. Product Portfolio

            18.3.16.3. SWOT Analysis

            18.3.16.4. Strategic Overview

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers